Insight Molecular Diagnostics Inc
Research Insight Molecular Diagnostics Inc (IMDX) on Bullrun: market cap USD 144.85M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIMDX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyUSD
- Market capUSD 144.85M
- Financial periodQ1 2026
- RevenueUSD 1.95M
- Net income-USD 4.29M
- Free cash flow-USD 8.25M
- Gross margin50.7%
Valuation Snapshot
latest market cap is USD 144.85M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 4.06M | -USD 50.22K | -USD 25.37M | 56.7% | -1.65 | USD 11.58M | USD 3.50M | -USD 31.46M |
| FY2024 | USD 1.88M | -USD 60.66K | -USD 21.21M | 39.3% | -4.66 | USD 8.64M | USD 3.66M | -USD 12.27M |
| FY2023 | USD 1.50M | -USD 27.78K | -USD 23.61M | 27.5% | -3.75 | USD 9.43M | n/a | USD 20.47M |
| FY2022 | USD 958.00K | -USD 72.90M | -USD 49.91M | -1.9% | -13.25 | USD 19.99M | n/a | USD 34.29M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 144.85M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 215.12M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 41.54M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 20.65M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 38.08M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 200.14M | n/a | n/a | n/a |
About Insight Molecular Diagnostics Inc
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Insight Molecular Diagnostics Inc's market cap?
Insight Molecular Diagnostics Inc's market capitalization is USD 144.85M.
What does Insight Molecular Diagnostics Inc do?
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies.